These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 30244085)

  • 41. Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation.
    He QL; Minn I; Wang Q; Xu P; Head SA; Datan E; Yu B; Pomper MG; Liu JO
    Angew Chem Int Ed Engl; 2016 Sep; 55(39):12035-9. PubMed ID: 27574181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Co-Delivery of Triptolide and Curcumin for Ovarian Cancer Targeting Therapy via mPEG-DPPE/CaP Nanoparticle.
    Liu L; Xiong X; Shen M; Ru D; Gao P; Zhang X; Huang C; Sun Y; Li H; Duan Y
    J Biomed Nanotechnol; 2018 Oct; 14(10):1761-1772. PubMed ID: 30041722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin.
    Zheng D; Duan C; Zhang D; Jia L; Liu G; Liu Y; Wang F; Li C; Guo H; Zhang Q
    Int J Pharm; 2012 Oct; 436(1-2):379-86. PubMed ID: 22732673
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Zeng H; Zhu X; Tian Q; Yan Y; Zhang L; Yan M; Li R; Li X; Wang G; Ma J; Su Y; Zhang X; Ma L; Zhang Z; Wu X
    Drug Deliv; 2020 Dec; 27(1):848-854. PubMed ID: 32508161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Triptolide and atorvastatin synergistically promote hepatotoxicity in cultured hepatocytes and female Sprague-Dawley rats by inhibiting pregnane X receptor-mediated transcriptional activation of CYP3A4.
    Zheng N; Wei A; Wu T; Long L; Yang H; Li H; Wang L
    Toxicol Lett; 2021 May; 342():85-94. PubMed ID: 33600922
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipid nanoparticles loading triptolide for transdermal delivery: mechanisms of penetration enhancement and transport properties.
    Gu Y; Yang M; Tang X; Wang T; Yang D; Zhai G; Liu J
    J Nanobiotechnology; 2018 Sep; 16(1):68. PubMed ID: 30217198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
    Cheng M; Ma D; Zhi K; Liu B; Zhu W
    Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of curcumin-loaded galactosylated chitosan-coated nanoparticles for targeted delivery of hepatocellular carcinoma.
    Huang M; Liu J; Fan Y; Sun J; Cheng JX; Zhang XF; Zhai BT; Guo DY
    Int J Biol Macromol; 2023 Dec; 253(Pt 6):127219. PubMed ID: 37802456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preparation and optimization of triptolide-loaded solid lipid nanoparticles for oral delivery with reduced gastric irritation.
    Zhang C; Gu C; Peng F; Liu W; Wan J; Xu H; Lam CW; Yang X
    Molecules; 2013 Oct; 18(11):13340-56. PubMed ID: 24172242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Redox-responsive self-assembly PEG nanoparticle enhanced triptolide for efficient antitumor treatment.
    Wang Y; Liu X; Wang X; Zheng W; Zhang J; Shi F; Liu J
    Sci Rep; 2018 Aug; 8(1):12968. PubMed ID: 30154488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
    Nasr M; Nafee N; Saad H; Kazem A
    Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment.
    Wang X; Zeng H; Zhu X; Xu D; Tian Q; Wang C; Zhao L; Zhao J; Miao M; Wu X
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute and subacute toxicity studies on triptolide and triptolide-loaded polymeric micelles following intravenous administration in rodents.
    Xu L; Qiu Y; Xu H; Ao W; Lam W; Yang X
    Food Chem Toxicol; 2013 Jul; 57():371-9. PubMed ID: 23583804
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer.
    Zheng S; Wang J; Ding N; Chen W; Chen H; Xue M; Chen F; Ni J; Wang Z; Lin Z; Jiang H; Liu X; Wang L
    J Nanobiotechnology; 2021 Nov; 19(1):381. PubMed ID: 34802453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low, but not high, dose triptolide controls neuroinflammation and improves behavioral deficits in toxic model of multiple sclerosis by dampening of NF-κB activation and acceleration of intrinsic myelin repair.
    Sanadgol N; Golab F; Mostafaie A; Mehdizadeh M; Khalseh R; Mahmoudi M; Abdollahi M; Vakilzadeh G; Taghizadeh G; Sharifzadeh M
    Toxicol Appl Pharmacol; 2018 Mar; 342():86-98. PubMed ID: 29407366
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes.
    Yuan ZX; Jia L; Lim LY; Lin JC; Shu G; Zhao L; Ye G; Liang XX; Ji H; Fu HL
    Int J Nanomedicine; 2017; 12():5673-5686. PubMed ID: 28848346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer.
    Chen Y; Yang J; Wang C; Wang T; Zeng Y; Li X; Zuo Y; Chen H; Zhang C; Cao Y; Sun C; Wang M; Cao X; Ge X; Liu Y; Zhang G; Deng Y; Peng C; Lu A; Lu J
    J Exp Clin Cancer Res; 2024 Jul; 43(1):207. PubMed ID: 39054545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of 3-O-β-D-galactosylated resveratrol-loaded polydopamine nanoparticles for hepatocellular carcinoma treatment.
    Shan X; Lv S; Cheng H; Zhou L; Gao Y; Xing C; Li D; Tao W; Zhang C
    Eur J Pharm Biopharm; 2024 Oct; 203():114454. PubMed ID: 39142541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SP94 Peptide-Functionalized PEG-PLGA Nanoparticle Loading with Cryptotanshinone for Targeting Therapy of Hepatocellular Carcinoma.
    Nie X; Liu Y; Li M; Yu X; Yuan W; Huang S; Ren D; Wang Y; Wang Y
    AAPS PharmSciTech; 2020 Apr; 21(4):124. PubMed ID: 32342227
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy
    Xiang Y; Huang W; Huang C; Long J; Zhou Y; Liu Y; Tang S; He DX; Tan XW; Wei H; Yu CY
    Mol Pharm; 2020 Sep; 17(9):3223-3235. PubMed ID: 32658485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.